Evidence map›Paper›PMID 33641057›Full record

ArticleAdvances in therapy2021

EGFR and PDL1: A Match (Not) Made in Heaven-A Real-World Retrospective Analysis of PDL1 Expression in EGFR-Mutated NSCLC.

Ullas Batra, Mansi Sharma, Shrinidhi Nathany, Abhishek Bansal, Sunil Pasricha, Parveen Jain, Anurag Mehta, Harkirat Singh

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ullas BatraDepartment of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 110085, India. ullasbatra@gmail.com.ORCID 0000-0003-3306-9824
Mansi SharmaDepartment of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 110085, India.
Shrinidhi NathanyMolecular Diagnostics, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 110085, India.
Abhishek BansalRadiology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 110085, India.
Sunil PasrichaPathology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 110085, India.
Parveen JainDepartment of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 110085, India.
Anurag MehtaLaboratory Services, Molecular Diagnostics and Transfusion Medicine, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 110085, India.
Harkirat SinghDepartment of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 110085, India.
Rajiv Gandhi Cancer Institute and Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEGFR (epidermal growth factor receptor) mutant NSCLC (non-small cell lung carcinoma) comprises 35-40% of cases in the Asian NSCLC cohort, compared to 15-20% in the rest of the world. Improved response rates have been observed in terms of PFS (progression-free survival) and ORR (overall response rate) when treated with EGFR TKIs (tyrosine kinase inhibitors). However, resistance eventually ensues regardless of the generation of TKI used. Preclinical studies have reported that PDL1 (programmed death ligand 1) is a downstream target of EGFR and is interposed by IL-6/JAK/STAT3 (interleukin-6/Janus kinase/signal transducer and activator of transcription 3), NF-κB (nuclear factor kappa beta), and p-ERK1/2/p-c-Jun pathways. Hence, it may potentially be repressed by EGFR TKIs. In this retrospective exploratory analysis, we studied whether PDL1 expression affects efficacy of EGFR TKIs and clinical outcome in patients with untreated metastatic EGFR-mutated lung adenocarcinoma.

methodsThis single-center retrospective, exploratory analysis was performed between January 2015 and December 2019. Among 1350 cases of NSCLC, 470 were EGFR mutant, of which PDL1 expression testing was done in 193 patients who were included in this study.

resultsMedian age was 60 years (range 24-87 years). A total of 116 patients (60.1%) had inframe deletion in exon 19, 52 (26.9%) had L858R, and 25 (13%) had uncommon mutations. The number of patients with PDL1 tumour proportion score (TPS) < 1% was 109 (56.5%); 1-49%, 57 (29.5%); and ≥ 50%, 27 (14%). Comparing clinical characteristics among various PDL1 groups, there were no statistically significant correlations obtained. However, patients with PDL1 > 50% were smokers, and showed a trend for higher disease burden at diagnosis. Median PFS of PDL1 < 1% was 10.14 months, compared to 9.4 months in the PDL1 > 1% group; however, the values did not reach statistical significance.

conclusionThe current study was an exploratory retrospective study; however, the results add to the growing body of evidence that PDL1 expression in EGFR-mutated NSCLC does not have any prognostic significance. Also the efficacy of EGFR TKIs is not influenced by variations in PDL1 TPS.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsAdultAgedAged, 80 and overB7-H1 AntigenErbB ReceptorsHumansMiddle AgedMutationProtein Kinase InhibitorsRetrospective StudiesTreatment OutcomeYoung AdultAntineoplastic AgentsB7-H1 AntigenCD274 protein, humanEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsEGFRImmune checkpointNon-small cell lung cancerPDL1

Identifiers

PMID33641057
OpenAlexW3134384205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.